-
Review
October 2, 2024
- Roles of X-box binding protein 1 in liver pathogenesis
- Jihoon Tak, Yun Seok Kim, Sang Geon Kim
- Clin Mol Hepatol. 2025;31(1):1-31.
-
Review
October 2, 2024
- Sinusoidal communication in chronic liver disease
- Albert Gibert-Ramos, María Andrés-Rozas, Raül Pastó, et al.
- Clin Mol Hepatol. 2025;31(1):32-55.
-
Review
October 21, 2024
- Bioactive metabolites: A clue to the link between MASLD and CKD?
- Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, et al.
- Clin Mol Hepatol. 2025;31(1):56-73.
-
Review
October 23, 2024
- Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations
- Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, et al.
- Clin Mol Hepatol. 2025;31(1):74-89.
-
Review
November 11, 2024
- Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment
- Atsumasa Komori, Yuki Kugiyama
- Clin Mol Hepatol. 2025;31(1):90-104.
-
Original Article
July 11, 2024
- Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)
- Chuan Liu, Hong You, Qing-Lei Zeng, et al.
- Clin Mol Hepatol. 2025;31(1):105-118.
-
Original Article
September 24, 2024
- Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial
- Woo Hyun Paik, Joo Kyung Park, Moon Jae Chung, et al.
- Clin Mol Hepatol. 2025;31(1):119-130.
-
Original Article
October 2, 2024
- Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation
- Soon Kyu Lee, Ho Joong Choi, Young Kyoung You, et al.
- Clin Mol Hepatol. 2025;31(1):131-146.
-
Original Article
October 2, 2024
- USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination
- Sha Hu, Zhouxiang Wang, Kun Zhu, et al.
- Clin Mol Hepatol. 2025;31(1):147-165.
-
Original Article
October 4, 2024
- Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness
- Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, et al.
- Clin Mol Hepatol. 2025;31(1):166-178.
-
Original Article
October 11, 2024
- Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments
- Carlos Jose Pirola, Maria Silvina Landa, Mariano Schuman, et al.
- Clin Mol Hepatol. 2025;31(1):179-195.
-
Original Article
October 15, 2024
- Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma
- Yang Liu, Fan Peng, Siyuan Wang, et al.
- Clin Mol Hepatol. 2025;31(1):196-212.
-
Original Article
October 17, 2024
- Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial
- Yao-Chun Hsu, Chi-Yi Chen, Cheng-Hao Tseng, et al.
- Clin Mol Hepatol. 2025;31(1):213-226.
-
Original Article
November 14, 2024
- Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis
- Nicholas A. Rouillard, Scott D. Barnett, Xinrong Zhang, et al.
- Clin Mol Hepatol. 2025;31(1):227-239.
-
Original Article
November 21, 2024
- Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis
- Anja Tiede, Lena Stockhoff, Zhaoli Liu, et al.
- Clin Mol Hepatol. 2025;31(1):240-255.
This archive contains links to the full-text of all issues of Clin Mol Hepatol.
Current issue
|
All issues
-
Clinical and
Molecular
HepatologyPrint ISSN: 2287-2728
Online ISSN: 2287-285X
-
-
Video abstract
-
- Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues
- Examining the therapeutic landscape of beta-blockers in portal hypertension
- Immunopathogenesis of liver fibrosis in steatotic liver disease
- Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
- Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
- The role of the hepatic autonomic nervous system
- HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
- Systemic therapy in advanced hepatocellular carcinoma
- Epidemiology and updated management for autoimmune liver disease
- Microbiome and metabolomics in alcoholic liver disease
- Personalized medicine in nonalcoholic fatty liver disease
- Acute on chronic liver failure in cirrhosis
- Current status and outcome of liver transplantation in South Korea
- History and future of hepatitis B virus control in South Korea
- Hepatocellular carcinoma statistics in South Korea
Impact Factor14.0First decision
07 Days
Publication after acceptance
03 Days
*Last 12 months
- MOST VIEWED (Last 6 months)
Viewed By
6392MAFLD: How is it different from NAFLD? Viewed By
5478Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma Viewed By
5154Global incidence and prevalence of nonalcoholic fatty liver disease Viewed By
4228Examining the therapeutic landscape of beta-blockers in portal hypertension Viewed By
4013Gut microbiome and metabolome signatures in liver cirrhosis-related complications
- MOST CITED (2023-2025)
Cited By
272Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma Cited By
230Global incidence and prevalence of nonalcoholic fatty liver disease Cited By
156MAFLD: How is it different from NAFLD? Cited By
79Non-alcoholic fatty liver disease: Definition and subtypes Cited By
76Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
|
|||||||
